About: A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry
Creator	Smith, Barbara Gadd, Michele Isakoff, J Kelly, Bridget Korotkin, Jenna Moy, · Nguyen, Anvy Specht, Michelle Spring, Laura Steven, ·
topic	covid:bd7a4446bdf5e718b52f296cb49561b22555ce5a#this
Source	Medline; PMC
abstract	PURPOSE: During the COVID-19 pandemic, most breast surgery for benign and malignant conditions has been postponed, creating a backlog of patients who will need surgery. A fair and transparent system for assessing the risk of further delaying surgery for individual patients to prioritize surgical scheduling is needed. METHODS: Factors related to risk of delaying surgery for breast patients were identified. Scores were assigned to each factor, with higher scores indicating a greater risk from delaying surgery. REDCap and Microsoft Excel tools were designed to track and score delayed patients. RESULTS: Published data and multidisciplinary clinical judgement were used to assign risk scores based on patient and tumor factors, length of delay, and tumor response to preoperative therapy. Patients completing neoadjuvant chemotherapy were assigned the highest scores as their options for delaying surgery are most limited. Among patients receiving neoadjuvant endocrine therapy or no medical therapy, higher scores were assigned for low-estrogen receptor or high-genomic risk scores, higher grade, larger tumors, younger age and longer delay. High priority scores were assigned for progression during preoperative therapy. Low scores were assigned for re-excisions, atypical lesions and other benign indications. There was good agreement of the tool’s ranking of sample patients with rankings by experienced clinicians. The tool generates risk-stratified patient lists by surgeon or institution to facilitate assignment of surgery dates. CONCLUSIONS: This tool generates a clinically consistent, risk-stratified priority list of breast surgical procedures delayed by the COVID-19 pandemic. This systematic approach may facilitate surgical scheduling as conditions normalize.
has issue date	2020-07-25(xsd:dateTime)
bibo:doi	10.1007/s10549-020-05792-2
bibo:pmid	32712878
has license	no-cc
sha1sum (hex)	bd7a4446bdf5e718b52f296cb49561b22555ce5a
schema:url	https://doi.org/10.1007/s10549-020-05792-2
resource representing a document's title	A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry
has PubMed Central identifier	PMC7382558
has PubMed identifier	32712878
schema:publication	Breast Cancer Res Treat
resource representing a document's body	covid:bd7a4446bdf5e718b52f296cb49561b22555ce5a#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/bd7a4446bdf5e718b52f296cb49561b22555ce5a
is schema:about of	named entity 'generates' named entity 'assessing' named entity 'breast' named entity 'limited' named entity 'surgical' named entity 'FACTOR' named entity 'IDENTIFIED' named entity 'OPTIONS' named entity 'INDICATIONS' named entity 'higher' named entity 'age' named entity 'younger' named entity 'scores' named entity 'Patients' named entity 'assigned' named entity 'systematic' named entity 'based' named entity 'fair' named entity 'surgery' named entity 'receiving' named entity 'higher grade' named entity 'scores' named entity 'tumors' named entity 'conditions' named entity 'surgeries' named entity 'malignant' named entity 'tumor' named entity 'COVID-19 pandemic' named entity 'neoadjuvant chemotherapy' named entity 'COVID-19 pandemic' named entity 'surgeon' named entity 'breast cancer' named entity 'risk stratification' named entity 'list' named entity 'neoadjuvant' named entity 'breast cancer' named entity 'tumors' named entity 'lumpectomy' named entity 'goserelin' named entity 'surgeon' named entity 'early-stage' named entity 'excisional biopsy' named entity 'Oncotype' named entity 'active surveillance' named entity 'critical care' named entity 'neoadjuvant' named entity 'endocrine therapy' named entity 'endocrine therapy' named entity 'endocrine therapy' named entity 'letrozole' named entity 'chemotherapy' named entity 'HER2' named entity 'breast cancers' named entity 'anastrozole' named entity 'tamoxifen' named entity 'diagnostic biopsy' named entity 'neoadjuvant' named entity 'DCIS' named entity 'Microsoft Excel' named entity 'COVID-19 pandemic' named entity 'neoadjuvant chemotherapy' named entity 'biopsies' named entity 'endocrine therapy' named entity 'surgical procedure' named entity 'Endocrine' named entity 'endocrine therapy' named entity 'breast cancer' named entity 'endocrine therapy' named entity 'tumor' named entity 'prognosis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software